LCMVgp33-41, the carboxyl-extended 11-aa-long peptide, is a sequence of lymphocytic choriomeningitis virus restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes. This is the H-2Db restricted epitope derived from the lymphocytic.
LCMVgp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].
GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with an SC50 of 344 nM. GP33-41 Epitope is a strong agonist of CD8 T cells.
LCMVGP (61-80) is a peptide fragment derived from LCMV glycoprotein (GP) and corresponds to amino acids 61-80. This specific epitope, LCMVGP (61-80), has the ability to elicit CD4+ T-cell response.